Features

There is no denying that machine learning and artificial intelligence (AI) are very much in vogue across the healthcare landscape. AI was a key topic in the president’s address by Mark Okusa, MD, FASN, at last year’s ASN Kidney Week in San Diego.

Acute kidney injury (AKI) does not discriminate in its impact. From the very young to the elderly, it can strike at any time, stems from a wide variety of causes, and demonstrates a complex variety of symptoms. The resulting kidney damage is often severe and life-threatening.

THE “R” FOR RENAL WAS RECENTLY ADDED TO ONE OF ASTRAZENECA’S THERAPEUTIC AREAS. WHAT LED TO THIS ADDITION OF “RENAL” TO THE CARDIO PLUS METABOLIC AREA?

Diabetes is the second most common cause of kidney failure in the United States. Diabetic Kidney Disease (DKD) encompasses structural and functional abnormalities involving the kidneys. Clinically, these changes result in hypertension, proteinuria, and progressive decline in kidney function, ultimately leading to ESKD. Diabetic kidney disease accounts for more than 40% of all ESKD In the United States.

In the era of evidence-based medicine, high-quality clinical trials are the key to the development of sound practice guidelines. Many landmark trials have enabled us to make significant progress in our approach to diabetic nephropathy, the leading cause of ESKD worldwide, although we are still short of a cure.

If it seems like you’ve been seeing more published papers on diabetic kidney disease in recent years, you’re not mistaken. The number of DKD studies has risen rapidly and steadily over the past two decades, according to a review and meta-analysis published in the journal Medicine. And this study included a time period prior to the more recent spate of clinical trials.

Pages